Francois-Clement Bidard

47PUBLICATIONS
238CO-AUTHORS
Tumour immunologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsMining engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (47)

|May 12, 2026
E-cadherin inactivation shapes tumor microenvironment specificities in invasive lobular breast cancer.

|Sep 29, 2025
Prognostic Significance and Predictive Value of Circulating Tumor Cells in Invasive Lobular Breast Carcinoma-An Exploratory Analysis of the STIC CTC Trial.

Jose Luis Sandoval, Nicolas Kiavue, Lounes Djerroudi

|Aug 22, 2025
Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.

François-Clément Bidard, Grégoire Gessain, Thomas Bachelot

|Jul 01, 2025
Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy.

Toulsie Ramtohul, Derek Lollivier, Justine Spriet

|Jun 02, 2025
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer.

François-Clément Bidard, Erica L Mayer, Yeon Hee Park

|Mar 18, 2025
Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis.

Wolfgang Janni, Thomas W P Friedl, Tracy C Yab

Pageof 8

Frequent Collaborators

10 joint publications

Luc Cabel

9 joint publications

Anne Vincent-Salomon

6 joint publications

Charlotte Proudhon

5 joint publications

Marc-Henri Stern